Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Seattle Genetics, Inc. (SGEN): A Billion-Dollar Anticancer Technology in the Making

Page 1 of 2

Anticancer drugs typically damage normal cells as well as cancer cells. Using a breakthrough technology, a midsize biotech company is developing a process to deliver anticancer drugs right inside a cancerous cell, selectively destroying it while sparing healthy cells. If successful, this will become a technology worth billions of dollars.

Monoclonal antibodies vs. conjugated antibodies

Monoclonal antibodies, or mAbs, block specific proteins that help cancer cells to grow. They may also boost the immune system of patients to fight against cancer cells. However, at present, they may not be as effective against large tumors as anticancer drugs.

Anticancer drugs, on the other hand, are very effective against large tumors. However, they have too much collateral damage. They destroy not just the disease, but also the patient, because they do not work in a targeted manner.

ADC technology

Seattle Genetics, Inc. (NASDAQ:SGEN)

The new technology being developed by Seattle Genetics, Inc. (NASDAQ:SGEN) among others, combines an mAb with an anticancer agent to create an entity called an antibody drug conjugate, or ADC. This combination selectively targets the protein found in cancer cells. In this manner, called the multiplier effect, it limits the damage done by an anticancer drug only to its real target, the cancer cell.

Seattle Genetics, Inc. (NASDAQ:SGEN) has developed Adcetris using this technology. It’s the only product approved by the FDA for treatment of patients with Hodgkin’s lymphoma and anaplastic large cell lymphoma (ALCL). The same molecule is going through nine other development programs for different cancer diseases. In addition, the company has four other ADC programs in the pipeline for targeting other forms of cancer.


Recently, Seattle Genetics signed a $520 million agreement with Bayer AG for its ADC technology. Under this contract, Seattle Genetics, Inc. (NASDAQ:SGEN) will receive $20 million as upfront payment for global rights to its technology, and $500 million as milestone and royalties on sales of its technology for several cancer diseases. Bayer will be responsible for R&D, manufacturing, and marketing of all products under the agreement.

Apart from Bayer, Seattle Genetics, Inc. (NASDAQ:SGEN) already has strong partnerships with leading pharma companies to support most of its pipeline products. Going forward, the company is expected to generate more than $3.5 billion in milestones and royalties from strategic alliances.

Prospective market

The overall oncology market is dominated by mAb therapies. The global mAb market is currently growing at a CAGR of 12% and likely to reach $32 billion by 2017, according to GBI Research. In the coming years, the ADC technology is expected to dominate the market, thanks to its enhanced efficiency and reduced side effects.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!